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Background: To compare outcomes for patients with recurrent or persistent papillary thyroid cancer (PTC) who
had metastatic tumors that were fluorodeoxyglucose-positron emission tomography (FDG-PET) positive or negative,
and to determine whether the FDG-PET scan findings changed the outcome of medical and surgical management.
Methods: From a prospective thyroid cancer database, we retrospectively identified patients with recurrent or
persistent PTC and reviewed data on demographics, initial stage, location and extent of persistent or recurrent
disease, clinical management, disease-free survival and outcome. We further identified subsets of patients who had
an FDG-PET scan or an FDG-PET/CT scan and whole-body radioactive iodine scans and categorized them by
whether they had one or more FDG-PET-avid (PET-positive) lesions or PET-negative lesions. The medical and
surgical treatments and outcome of these patients were compared.
Results: Between 1984 and 2008, 41 of 141 patients who had recurrent or persistent PTC underwent FDG-PET
(n = 11) or FDG-PET/CT scans (n = 30); 22 patients (54%) had one or more PET-positive lesion(s), 17 (41%) had
PET-negative lesions, and two had indeterminate lesions. Most PET-positive lesions were located in the neck (55%).
Patients who had a PET-positive lesion had a significantly higher TNM stage (P = 0.01), higher age (P = 0.03), and
higher thyroglobulin (P = 0.024). Only patients who had PET-positive lesions died (5/22 vs. 0/17 for PET-negative
lesions; P = 0.04). In two of the seven patients who underwent surgical resection of their PET-positive lesions,
loco-regional control was obtained without evidence of residual disease.
Conclusion: Patients with recurrent or persistent PTC and FDG-PET-positive lesions have a worse prognosis. In
some patients loco-regional control can be obtained without evidence of residual disease by reoperation if the
lesion is localized in the neck or mediastinum.Background
Papillary thyroid cancer (PTC) accounts for 80 to 85% of
all thyroid cancers. Although most patients with PTC
have a good prognosis, recurrent disease develops in
about 20 to 30%, and about 7% of patients die from pro-
gressive disease within 10 years of diagnosis [1]. After
initial surgery for PTC, follow-up consists of regular* Correspondence: Quan-Yang.Duh@ucsfmedctr.org
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distribution, and reproduction in any mediumultrasound examination of the neck, measurements of
serum thyroglobulin (Tg) and Tg antibodies, and whole-
body iodine scans (WBS) [2]. Patients who have recur-
rent or persistent disease usually have increased serum
Tg levels. Recurrent PTC can be identified best by ultra-
sound imaging of the neck, increased basal or stimulated
serum Tg levels, and whole-body iodine scans. Meta-
static PTC tumors can be identified by radioactive iodine
scans, because well-differentiated thyroid cells often take
up and concentrate iodine [3].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ciated with worse survival [4]. The sites where iodine
uptake is negative in patients with recurrent or persist-
ent PTC may be localized with fluorodeoxyglucose-
positron emission tomography (FDG-PET) or FDG-PET-
computed tomography (FDG-PET/CT). Both FDG-PET
scans and FDG-PET/CT scans are especially useful for
identifying the site of recurrent or persistent disease in
patients who have increased serum Tg levels and nega-
tive whole-body iodine scans [5]. The sensitivity of FDG-
PET scans (63 to 95%) and FDG-PET/CT scans (66 to
98%) is similar in patients with well-differentiated thy-
roid cancer, increased Tg levels and negative whole-body
scans [6], but FDG-PET scans (0 to 25% [7]) have much
lower specificity than do FDG-PET/CT scans (81% [6]).
The positive predictive value of FDG-PET/CT ranges be-
tween 92 and 100% [8,9] and the negative predictive
value is about 27% [9].
Metastatic PTCs that are FDG-PET-positive, but
radioactive iodine negative, often have a higher malig-
nant histological grade than the primary tumor, a pattern
that is less common for FDG-PET-negative PTCs [10].
Furthermore, PTCs that are FDG-PET positive and have
a higher maximum standard uptake value (SUV max)
are associated with a worse prognosis [11]. Whether the
more aggressive nature of these FDG-PET-positive PTCs
in the neck warrants more aggressive surgical therapy is
not unknown. To address this question, we compared
the outcome of patients with recurrent or persistent
PTC according to whether the cancer was positive or
negative on FDG-PET or FDG-PET/CT scans. We also
determined the outcome and surgical management of
lesions that were FDG-PET or FDG-PET/CT positive.
Methods
Data collection
After obtaining approval from our institutional review
board, we searched the database of the California Cancer
Registry to identify all patients with PTC treated at the
University of California San Francisco (UCSF) between
1984 and 2008. Some of these patients were referred to
UCSF because of recurrent or persistent disease after
having their initial treatment at other medical centers.
For all patients with recurrent or persistent PTC, we
recorded data on demographics, initial stage of PTC,
thyroglobulin (Tg) levels at initial presentation, location
and number of recurrences, disease-free survival and out-
come including Tg levels to define outcome. Persistent of
recurrent disease was defined by evidence of disease on
imaging studies or elevated Tg levels postoperatively or
during follow-up
We further identified the subset of patients who had
either an FDG-PET scan or an FDG-PET/CT scan and a
whole-body radioactive iodine (131I) scan, and categorizedthem by whether they had one or more FDG-PET-avid
(PET-positive) lesions or PET-negative lesions. The med-
ical and surgical treatment and outcome of these patients
were then compared. A common indication for a FDG-
PET scan was an elevated blood Tg level and a negative
131I scan. We reviewed all reports of the FDG-PET and
FDG-PET/CT scans and documented the number of
FDG-PET-positive lesions and the standard uptake value
of these FDG-PET-avid lesions. The sites of the metastases
were also recorded.Statistical analysis
Data are presented as mean ± standard deviation (SD)
or median and interquartile range based on the distribu-
tion of data. T-tests, Mann–Whitney U tests and chi-
square tests were used as appropriate to compare groups.
A P value <0.05 was considered statistically significant. All
analyses were done using SPSS 16.0 (SPSS Inc., Chicago,
IL, USA).Results
For the 24-year period, 1052 patients with PTC were iden-
tified, 141 of whom had recurrent or persistent PTC.
There were nearly twice as many women as men, and the
mean age was 46 years (Table 1). Forty-one patients (29%)
underwent an FDG-PET scan, of which thirty were FDG-
PET/CT scans. Twenty-two patients (54%) had one or
more lesions that were FDG-PET-positive, seventeen
(41%) had a FDG-PET-negative lesion, and two (5%) had a
lesion with uncertain uptake (Figure 1). FDG-PET-positive
lesions were most often seen in the neck (41%), followed
by neck and lung (25%), lungs (17%), and multiple sites
(13%). The median standard uptake value was 4.20 g/ml
(range 1.5 to 29).
The clinical characteristics of patients with FDG-PET-
positive and FDG-PET-negative tumors are listed in
Table 1. Patients with positive PET lesions were signifi-
cantly older (P = 0.03), had higher median serum thyro-
globulin levels at the time of evaluation (32.9 versus
3.1 μl/L) (P = 0.024) and had a higher tumor, node, me-
tastasis (TNM) stage (P = 0.01). Patients with positive
lesions also had larger tumors although this was not sta-
tistically different. Despite the slightly lower 131I uptake
in patients with PET-positive lesions, patients whose
lesions were 131I negative were treated surprisingly more
frequently with 131I (Table 2). Disease-free survival was
similar between the two groups, but only patients with
PET-positive lesions died of recurrent or persistent dis-
ease (five out of twenty-two versus none out of seven-
teen, P = 0.04) (Table 2). Three of these patients died of
metastatic PTC. One additional patient who died of an
unknown cause and another who died of endocarditis
had extensive metastatic disease. The lesions of the two
Table 1 Characteristics of patients with FDG-PET-positive









51 (±21) 44+/−21 0.03
Gender male:female 10:12 6:11 n.s.
Initial TNM stage 0.01
Stage 1 4 9
Stage 2 0 1
Stage 3 10 1


















32.9 (0.9#-1500) 3.1 (0.3#-300) 0.024
*Average age of the total 141patients with recurrent PTC is 46 ± 20 years. #Six
patients had normal Tg levels at the time of recurrence. The diagnosis was
made on the following imaging modalities. n = 3 recurrence on PET scan. One
of them had an initial T4 tumor. n = 3 Recurrence on iodine scan n = 1,
unclear, but PET-positive lesion on PET scan. FDG-PET, fluorodeoxyglucose-
positron emission tomography; n.s., not significant; SD, standard deviation;
TNM, tumor, node, metastasis.
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current disease.
Seven patients underwent surgical resection of a recur-
rent FDG-PET-positive lesion(s) and seven patients
underwent surgical resection of a FDG-PET-negative le-
sion (Table 3). In one of these patients with a PET-
positive lesion, loco-regional control was obtained with-
out evidence of residual disease after a mediastinal lesion
(Tg 0.2 μg/L) was resected and all scanning tests were
negative seven years after reoperation. Another patient
had no evidence of residual disease on an ultrasound of
the neck, whole-body iodine scan and PET scan; the Tg
level was 3.8 μg/L four years after PET-positive metasta-
ses were removed. One patient who had a PET-positive
lesion in the neck and underwent surgical resection died
of metastatic thyroid cancer. Of the patients with a
FDG-PET-negative lesion who underwent surgical resec-
tion, one patient had no signs of residual disease and a
Tg level of 0.9 μg/L at follow-up, indicating potential
cure. Four other patients who died did not undergo sur-
gical resection of their PET-positive lesions, primarily
because of the presence of diffuse pulmonary, hepatic orbone metastasis or sites in the head and neck region that
were less accessible for removal. In the PET-negative
group, in two patients loco-regional control was
obtained without evidence of residual disease, one after
a removal of a metastatic cervical lymph node from the
neck, and another with radioactive iodine therapy. The
remainder of patients in both groups had stable or pro-
gressive disease (Table 3).
Discussion
FDG-PET and FDG-PET/CT can help identify metastatic
thyroid cancer in patients with recurrent or persistent
PTC who have increased serum thyroglobulin levels and
negative or equivocal whole-body iodine scans [3,8,12].
Metastatic PTCs that lose the ability to concentrate
radioactive iodine are believed to be clinically more ag-
gressive and have a worse outcome, probably because
they are less well-differentiated and cannot be treated
successfully with radioactive iodine therapy. Papillary
thyroid cancers that are radioactive iodine negative take
up FDG-PET more readily because of their higher meta-
bolic activity [3].
When we compared the outcome of patients with re-
current or persistent PTC who had FDG-PET-positive or
FDG-PET-negative metastatic tumors, we found that
patients who had positive lesions had larger tumors at
the time of initial treatment. Furthermore, in these
patients the initial TNM stage was higher than in
patients who had a negative lesion. These patients also
had higher serum thyroglobulin levels at the time of the
FDG-PET scan. In our cohort study, only patients with
FDG-PET-positive lesions died. Although our sample
size is relatively small, this observation supports previ-
ous reports that PET-positive lesions are associated with
a worse prognosis [3]. One of those previous studies
showed that patients with PET-positive lesions were also
older, had a higher initial cancer stage and higher thyro-
globulin levels [11]. These risk factors indicate that PET-
positive patients have extensive and more aggressive
PTC and are more likely to have either recurrent or per-
sistent thyroid cancer. Another study found that most
patients with PET-positive metastases also had high-risk
clinical characteristics like extensive extrathyroidal ex-
tension of the primary tumor, and that 70% of patients
with PTC had less well-differentiated metastases than
found in their primary tumors [10].
In our study, in only two of seven patients with PET-
positive neck lesions who underwent reoperation loco-
regional control was obtained without evidence of residual
disease. One of these patients had a mediastinal lymph
node metastasis resected. The other patient had two
lymph nodes resected and had no evidence of residual dis-
ease on imaging studies four years after surgery, but the
thyroglobulin level remained elevated. Although one
Figure 1 Flow chart showing patient selection and outcome for patients with PTC treated at the University of California San Francisco
between 1984 and 2008.
Table 2 Comparison of outcomes for patients with FDG-
















5 (23%) 8 (47%) n.s.
131I uptake in PET-







10 (46%) 6 (41%) n.s.
Outcome, n (%) n.s.




2 (10%)* 2 (13%)
Progressive disease 9 (43%) 9 (56%)
Death† 5 (18%)† 0 (0%)†
Unknown 1
*One of the two patients had no evidence of recurrent disease, although the
Tg level was 3.8 ng/l. †There was a significant difference for ‘death’ between
the PET + and PET– group (P = 0.04). 131I, whole-body radioactive iodine scan;
FDG-PET, fluorodeoxyglucose-positron emission tomography; n.s., not
significant.
Schreinemakers et al. World Journal of Surgical Oncology 2012, 10:192 Page 4 of 7
http://www.wjso.com/content/10/1/192might question why palliative reoperations were done in
patients with distant metastasis, we believe that surgical
resection of PET-positive lesions in the neck is indicated
to control loco-regional disease. One might anticipate that
PET-positive lesions would grow faster and be more likely
to cause local morbidity. We realize that there could be a
bias in our series. It is known that patients with FDG-
PET-positive lesions have more aggressive disease and,
therefore, the FDG-PET scans may have been performed
more readily in patients suspected of more aggressive dis-
ease. Although we failed to show a clear benefit of surgical
resection in this study, we believe that resection of recur-
rent or persistent neck lesions should usually be per-
formed especially for recurrent tumors that are growing
or are larger than 1 cm.
In our study, all FDG-PET-positive lesions that were
resected were either palpable or seen on an ultrasound
of the neck or magnetic resonance image (MRI) of the
mediastinum. Ultrasound is generally more sensitive for
identifying nodal metastases in the neck than FDG-PET
and FDG-PET/CT [13]. Ultrasound-guided needle bi-
opsy can provide a definitive diagnosis. In two patients,
the decision to operate was made regardless of the FDG-
PET scan result.
In a previous study, the impact of FDG-PET/CT for
recurrent PTC on the clinical management changed the
treatment plan in 40% of 33 patients, supported the
treatment plan made before the PET scan in 27%, and
failed to contribute to the management in 33% [9].
Table 3 Surgical treatment and outcome of patients with FDG-PET-avid recurrent papillary thyroid cancer
Patient Location of FDG-PET-avid
lesions
Surgical indication Operative details Outcome after surgical treatment of FDG-
PET-avid lesion
1 Neck lesions, levels 2 and 3 Palpable mass, level 2/3 Dissection upper neck,
left side
Persistent disease;
FNA: metastatic PTC Tg 56.5 μg/L,
no more PET-positive lesions;
ultrasound:
multiple small nodes <1 cm
2 Two neck lesions, right side;
jugular node
Palpable lymph node,
right side of the neck
Right-sided neck
dissection
Loco-regional control without evidence of residual
disease after surgical resection of both lesions;
Tg 33.5 low Tg levels (3.8 μg/L);
ultrasound without evidence of suspicious lymph
nodes in the neck;
negative PET scan and a negative whole-body iodine
scan after four years of follow-up
3 Neck lesion Lesion detected on
ultrasound: size 1.2 cm
Lymph node resection
in the central neck
Progressive disease
FNA: recurrent tumor PET-positive lesions in the neck and lungs
4 Neck lesion Palpable lesion near
right clavicle.
Right neck dissection Died
Tg level was 63.8 μg/L.
5 Neck and lung metastases Lesion detected on
ultrasound: size 1 cm.
Central neck dissection Progressive disease
Tg level was 8.6 μg/L Tg level increased from 7.9 to 17 μg/L
PET scan showed lung metastasis but no residual
disease in the neck
6 Neck lesion; PET scan initially
interpreted as negative, but
later interpreted as positive
Palpable mass of 2.3 cm
near the left mandible, also
shown by ultrasound
Several small nodes




7 Solitary mediastinal lesion Lesion also seen on MRI,




Loco-regional control without evidence of residual
disease: Tg level decreased to 0.2 μg/L up until seven
years of follow-up;
Tg level was 12 μg/L ultrasound showed no residual disease in neck;
No ultrasound CT scan two years after treatment showed no
evidence of pulmonary metastasis
FDG-PET/CN, fluorodeoxyglucose-positron emission tomography/computed tomography; FNA, fine needle aspiration; MRI, magnetic resonance imaging; PTC,
papillary thyroid cancer; Tg, thyroglobulin.
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globulin levels were greater than 10 ng/ml. In that study,
22 out of 30 patients were treated surgically. However,
they did not show the outcome of these patients. An-
other study that evaluated the clinical value of FDG-PET
scans in 37 patients who had an increased thyroglobulin
level and a negative whole-body iodine scan found that
28 patients had a positive PET scan. In 29 patients, the
management of these patients appears to have changed
from the initial treatment plan (23 underwent surgery,
14 of whom were disease-free after a mean of six
months [14]. FDG-PET/CT scan may contribute to the
surgical strategy in patients with persistent or recurrent
PTC.In our study, 23% of patients with PET-positive lesions
had metastatic lesions that took up radioactive iodine.
This is a lower percentage than the 37.5% reported pre-
viously [11]. In that study, prognosis was surprisingly
worse in patients who had both PET-positive lesions and
radioactive iodine uptake, and survival was similar,
whether their lesions did or did not take up radioactive
iodine [11]. We were surprised to find that among our
patients who had PET- positive lesions that were less likely
to take up radioactive iodine, yet more were treated with
radioactive iodine than patients with PET-negative lesions.
In a report of the Memorial Sloan Kettering Cancer
Center experience, patients with PET-positive lesions were
treated with higher doses of radioactive iodine than those
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radioactive iodine, subsequent FDG-PET uptake was simi-
lar after one year, the PET volume of the lesions was lar-
ger, and the thyroglobulin level was also higher after one
year of follow-up [15].
The results of reoperations of patients with PET-
positive lesions have been studied before by Mirallie
et al. In that series, patients with recurrent differentiated
thyroid cancer and FDG-PET-positive lesions underwent
surgical resection. Half of these patients had no evidence
of residual disease. A subgroup of these patients even
had no detectable thyroglobulin levels indicating cure
[16]. However, the prognosis of patients with FDG-PET-
positive lesions and PDG-PET-negative lesions after
surgery remains unclear. Nevertheless, our study had
several limitations: its retrospective design, relatively
small sample size, and inability to obtain histological
confirmation for all FDG-PET and FDG-PET/CT lesions.
Moreover, using FDG-PET scanning to localize recurrent
or persistent PTC has some established disadvantages.
First, it has relatively low sensitivity, specificity and posi-
tive predictive value. Second, it is expensive. Third, the
decision to operate does not always depend on the scan
results, which are certainly of most value in patients
who have elevated thyroglobulin levels, but are radio-
active iodine negative and also have other negative scans.
However, FDG-PET scanning can document patients
with multiple distant metastases who are not candidates
for reoperation.
Conclusion
In conclusion, patients with recurrent or persistent PTC
that are FDG-PET scan positive have a worse prognosis,
although some can be potentially cured by reoperation
after resection of metastatic tumors in the neck or medi-
astinum. We believe that localized neck lesions that are
FDG-PET scan positive should be resected.
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